Harvard Medical School & Dutch present new work on OV.
Some of the stuff that Matt was talking about during the Canaccord fireside chat on August 12th, which demonstrates how ONCY's OV pelareorep changes the dynamics of the tumor microenvironment (TME) for that of an immunosuppressive TME to that of conducive TME that supports the addition of checkpoint inhibitors when pelareorep is administered beforehand. Remember that pelareorep "primes" the adaptive immunes system to enable the synergistic effects of immune checkpoint treatment, and the Harvard Medical School work supports this understanding by demonstrating one of the many pathways that pelareorep influences.
". In the context of oncolytic virotherapy, macrophages were initially thought to predominantly contribute to anti-viral responses, impeding viral spread. However, macrophages have now also been found to mediate transport of OV particles and, after TME infiltration, to be subjected to a phenotypic shift that renders them pro-inflammatory and tumour-suppressive."
The Multifaceted Role of Macrophages in Oncolytic Virotherapy - August 09, 2021
Laura Hofman 1 , Sean E. Lawler 2 and Martine L. M. Lamfers 1,
1 Department of Neurosurgery, Brain Tumor Center, Erasmus Medical Center, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands; l.hofman@students.uu.nl 2 Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02115, USA; slawler@bwh.harvard.edu *